{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T13:08:07Z","timestamp":1783775287807,"version":"3.55.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,8,5]],"date-time":"2014-08-05T00:00:00Z","timestamp":1407196800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1038\/npp.2014.195","type":"journal-article","created":{"date-parts":[[2014,9,24]],"date-time":"2014-09-24T07:02:13Z","timestamp":1411542133000},"page":"472-479","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["The Dopamine Stabilizer (\u2212)-OSU6162 Occupies a Subpopulation of Striatal Dopamine D2\/D3 Receptors: An [11C]Raclopride PET Study in Healthy Human Subjects"],"prefix":"10.1038","volume":"40","author":[{"given":"Nelleke","family":"Tolboom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk W","family":"Berendse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josee E","family":"Leysen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maqsood","family":"Yaqub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart NM","family":"van Berckel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C","family":"Schuit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirthe M","family":"Ponsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Bakker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikie J","family":"Hoetjes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert D","family":"Windhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria L","family":"Carlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriaan A","family":"Lammertsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvid","family":"Carlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,8,5]]},"reference":[{"key":"BFnpp2014195_CR1","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.neuroimage.2013.05.091","volume":"82","author":"K Alakurtti","year":"2013","unstructured":"Alakurtti K, Johansson JJ, Tuokkola T, N\u00e4gren K, Rinne JO (2013). Rostrocaudal gradients of dopamine D2\/3 receptor binding in striatal subregions measured with [11C]raclopride and high-resolution positron emission tomography. Neuroimage 82: 252\u2013259.","journal-title":"Neuroimage"},{"key":"BFnpp2014195_CR2","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s00213-004-1826-6","volume":"175","author":"RA Bressan","year":"2004","unstructured":"Bressan RA, Erlandsson K, Spencer EP, Ell PJ, Pilowsky LS (2004). Prolactinemia is uncoupled from central D2\/D3 dopamine receptor occupancy in amisulpride treated patients. Psychopharmacology (Berl) 175: 367\u2013373.","journal-title":"Psychopharmacology (Berl)"},{"key":"BFnpp2014195_CR3","first-page":"1614","volume":"38","author":"G Brix","year":"1997","unstructured":"Brix G, Zaers J, Adam LE, Bellemann ME, Ostertag H, Trojan H et al (1997). Performance evaluation of a whole-body PET scanner using the NEMA protocol. National Electrical Manufacturers Association. J Nucl Med 38: 1614\u20131623.","journal-title":"J Nucl Med"},{"key":"BFnpp2014195_CR4","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1007\/s00702-011-0701-y","volume":"118","author":"ES Burstein","year":"2011","unstructured":"Burstein ES, Carlsson ML, Owens M, Ma JN, Schiffer HH, Carlsson A et al (2011). II. In vitro evidence that (\u2212)-OSU6162 and (+)-OSU6162 produce their behavioral effects through 5-HT2A serotonin and D2 dopamine receptors. J Neural Transm 118: 1523\u20131533.","journal-title":"J Neural Transm"},{"key":"BFnpp2014195_CR5","doi-asserted-by":"crossref","first-page":"137","DOI":"10.31887\/DCNS.2006.8.1\/acarlsson","volume":"8","author":"A Carlsson","year":"2006","unstructured":"Carlsson A, Carlsson ML (2006). A dopaminergic deficit hypothesis of schizophrenia: the path to discovery. Dialogues Clin Neurosci 8: 137\u2013142.","journal-title":"Dialogues Clin Neurosci"},{"key":"BFnpp2014195_CR6","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1007\/s00702-011-0704-8","volume":"118","author":"ML Carlsson","year":"2011","unstructured":"Carlsson ML, Burstein ES, Kloberg A, Hansson S, Schedwin A, Nilsson M et al (2011). I. In vivo evidence for partial agonist effects of (\u2212)-OSU6162 and (+)-OSU6162 on 5-HT2A serotonin receptors. J Neural Transm 118: 1511\u20131522.","journal-title":"J Neural Transm"},{"key":"BFnpp2014195_CR7","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2174\/0929867043456034","volume":"11","author":"ML Carlsson","year":"2004","unstructured":"Carlsson ML, Carlsson A, Nilsson M (2004). Schizophrenia: from dopamine to glutamate and back. Curr Med Chem 11: 267\u2013277.","journal-title":"Curr Med Chem"},{"key":"BFnpp2014195_CR8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ejphar.2009.11.025","volume":"628","author":"T Dyhring","year":"2010","unstructured":"Dyhring T, Nielsen EO, Sonesson C, Pettersson F, Karlsson J, Svensson P et al (2010). The dopaminergic stabilizers pridopidine (ACR16) and (\u2212)-OSU6162 display dopamine D(2) receptor antagonism and fast receptor dissociation properties. Eur J Pharmacol 628: 19\u201326.","journal-title":"Eur J Pharmacol"},{"key":"BFnpp2014195_CR9","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1002\/jlcr.2580240808","volume":"24","author":"E Ehrin","year":"1987","unstructured":"Ehrin E, Gawell L, Hogberg T, de Paulis T, Strom P (1987). Synthesis of [methoxy-3H]- and [methoxy-11C]-labelled raclopride. Specific dopamine-D2 receptor ligands. J Labell Compounds Radiopharm 24: 931\u2013940.","journal-title":"J Labell Compounds Radiopharm"},{"key":"BFnpp2014195_CR10","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0028-3908(98)00200-7","volume":"38","author":"A Ekesbo","year":"1999","unstructured":"Ekesbo A, Torstenson R, Hartvig P, Carlsson A, Sonesson C, Waters N et al (1999). Effects of the substituted (S)-3-phenylpiperidine (\u2212)-OSU6162 on PET measurements of [11C]SCH23390 and [11C]raclopride binding in primate brains. Neuropharmacology 38: 331\u2013338.","journal-title":"Neuropharmacology"},{"key":"BFnpp2014195_CR11","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1001\/archpsyc.1992.01820070032005","volume":"49","author":"L Farde","year":"1992","unstructured":"Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G (1992). Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 49: 538\u2013544.","journal-title":"Arch Gen Psychiatry"},{"key":"BFnpp2014195_CR12","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0924-977X(00)00133-4","volume":"11","author":"O Gefvert","year":"2001","unstructured":"Gefvert O, Lundberg T, Wieselgren IM, Bergstrom M, Langstrom B, Wiesel F et al (2001). D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study. Eur Neuropsychopharmacol 11: 105\u2013110.","journal-title":"Eur Neuropsychopharmacol"},{"key":"BFnpp2014195_CR13","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1017\/S1092852900015650","volume":"12","author":"HJ Groenewegen","year":"2007","unstructured":"Groenewegen HJ (2007). The ventral striatum as an interface between the limbic and motor systems. CNS Spectr 12: 887\u2013892.","journal-title":"CNS Spectr"},{"key":"BFnpp2014195_CR14","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/nchembio.199","volume":"5","author":"Y Han","year":"2009","unstructured":"Han Y, Moreira IS, Urizar E, Weinstein H, Javitch JA (2009). Allosteric communication between protomers of dopamine class A GPCR dimers modulates activation. Nat Chem Biol 5: 688\u2013695.","journal-title":"Nat Chem Biol"},{"key":"BFnpp2014195_CR15","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1038\/sj.jcbfm.9600493","volume":"27","author":"RB Innis","year":"2007","unstructured":"Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN et al (2007). Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 27: 1533\u20131539.","journal-title":"J Cereb Blood Flow Metab"},{"key":"BFnpp2014195_CR16","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/j.1601-5215.2012.00678.x","volume":"24","author":"B Johansson","year":"2012","unstructured":"Johansson B, Carlsson A, Carlsson ML, Karlsson M, Nilsson MKL, Nordquist-Brandt E et al (2012). Placebo-controlled cross-over study of the monoaminergic stabiliser (\u2212)-OSU6162 in mental fatigue following stroke or traumatic brain injury. Acta Neuropsychiatr 24: 266\u2013274.","journal-title":"Acta Neuropsychiatr"},{"key":"BFnpp2014195_CR17","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1001\/archpsyc.57.6.553","volume":"57","author":"S Kapur","year":"2000","unstructured":"Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, Seeman P (2000). A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry 57: 553\u2013559.","journal-title":"Arch Gen Psychiatry"},{"key":"BFnpp2014195_CR18","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1111\/j.1471-4159.2009.06554.x","volume":"112","author":"E Kara","year":"2010","unstructured":"Kara E, Lin H, Strange PG (2010a). Co-operativity in agonist binding at the D2 dopamine receptor: evidence from agonist dissociation kinetics. J Neurochem 112: 1442\u20131453.","journal-title":"J Neurochem"},{"key":"BFnpp2014195_CR19","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1111\/j.1476-5381.2010.01010.x","volume":"161","author":"E Kara","year":"2010","unstructured":"Kara E, Lin H, Svensson K, Johansson AM, Strange PG (2010b). Analysis of the actions of the novel dopamine receptor-directed compounds (S)-OSU6162 and ACR16 at the D2 dopamine receptor. Br J Pharmacol 161: 1343\u20131350.","journal-title":"Br J Pharmacol"},{"key":"BFnpp2014195_CR20","unstructured":"Kloberg A, Constantinescu R, Nilsson MKL, Carlsson ML, Carlsson A, Wahlstr\u00f6m J et al (2014). Tolerability and efficacy of the monoaminergic stabilizer (\u2212)-OSU6162 (PNU-96391A) in Huntington's disease: a double-blind cross-over study. Acta Neuropsychiatrica (doi:10.1017\/neu.2014.16)."},{"key":"BFnpp2014195_CR21","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1007\/s00702-007-0784-7","volume":"114","author":"RA Lahti","year":"2007","unstructured":"Lahti RA, Tamminga CA, Carlsson A (2007). Stimulating and inhibitory effects of the dopamine \u2018stabilizer\u2019 (\u2212)-OSU6162 on dopamine D2 receptor function in vitro. J Neural Transm 114: 1143\u20131146.","journal-title":"J Neural Transm"},{"key":"BFnpp2014195_CR22","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1124\/jpet.111.190702","volume":"342","author":"X Langlois","year":"2012","unstructured":"Langlois X, Megens A, Lavreysen H, Atack J, Cik M, te RP et al (2012). Pharmacology of JNJ-37822681, a specific and fast-dissociating D2 antagonist for the treatment of schizophrenia. J Pharmacol Exp Ther 342: 91\u2013105.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFnpp2014195_CR23","first-page":"473","volume-title":"Handbook of Experimental Pharmacology","author":"JE Leysen","year":"2002","unstructured":"Leysen JE (2002). Atypical antipsychotics. In: Di Chiara G, eds. Handbook of Experimental Pharmacology Vol 154\/II. Springer Verlag: Berlin, Heidelberg, Germany. pp 473\u2013490."},{"key":"BFnpp2014195_CR24","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1109\/42.563664","volume":"16","author":"F Maes","year":"1997","unstructured":"Maes F, Collignon A, Vandermeulen D, Marchal G, Suetens P (1997). Multimodality image registration by maximization of mutual information. IEEE Trans Med Imaging 16: 187\u2013198.","journal-title":"IEEE Trans Med Imaging"},{"key":"BFnpp2014195_CR25","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1097\/01.WCB.0000048520.34839.1A","volume":"23","author":"D Martinez","year":"2003","unstructured":"Martinez D, Slifstein M, Broft A, Mawlawi O, Hwang DR, Huang Y et al (2003). Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metab. 23: 285\u2013300.","journal-title":"J Cereb Blood Flow Metab."},{"key":"BFnpp2014195_CR26","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1097\/00004647-200109000-00002","volume":"21","author":"O Mawlawi","year":"2001","unstructured":"Mawlawi O, Martinez D, Slifstein M, Broft A, Chatterjee R, Hwang DR et al (2001). Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and precision of D(2) receptor parameter measurements in ventral striatum. J Cereb Blood Flow Metab 21: 1034\u20131057.","journal-title":"J Cereb Blood Flow Metab"},{"key":"BFnpp2014195_CR27","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1124\/jpet.106.102905","volume":"318","author":"S Natesan","year":"2006","unstructured":"Natesan S, Svensson KA, Reckless GE, Nobrega JN, Barlow KB, Johansson AM et al (2006). The dopamine stabilizers (S)-(\u2212)-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(\u2212)-OSU6162] and 4-(3-methanesulfonylphenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for motor side effects in the rat. J Pharmacol Exp Ther 318: 810\u2013818.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFnpp2014195_CR28","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.eurpsy.2007.02.005","volume":"22","author":"L Pani","year":"2007","unstructured":"Pani L, Pira L, Marchese G (2007). Antipsychotic efficacy: relationship to optimal D2-receptor occupancy. Eur Psychiatry 22: 267\u2013275.","journal-title":"Eur Psychiatry"},{"key":"BFnpp2014195_CR29","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1177\/0091270003262792","volume":"44","author":"CA Rodriguez","year":"2004","unstructured":"Rodriguez CA, Azie NE, Adams G, Donaldson K, Francom SF, Staton BA et al (2004). Single oral dose safety, tolerability, and pharmacokinetics of PNU-96391 in healthy volunteers. J Clin Pharmacol 44: 276\u2013283.","journal-title":"J Clin Pharmacol"},{"key":"BFnpp2014195_CR30","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s00702-008-0038-3","volume":"115","author":"JP Rung","year":"2008","unstructured":"Rung JP, Rung E, Helgeson L, Johansson AM, Svensson K, Carlsson A et al (2008). Effects of (\u2212)-OSU6162 and ACR16 on motor activity in rats, indicating a unique mechanism of dopaminergic stabilization. J Neural Transm 115: 899\u2013908.","journal-title":"J Neural Transm"},{"key":"BFnpp2014195_CR31","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00210-011-0641-y","volume":"384","author":"JP Rung","year":"2011","unstructured":"Rung JP, Rung E, Johansson AM, Svensson K, Carlsson A, Carlsson ML (2011). Effects of the dopamine stabilizers (S)-(\u2212)-OSU6162 and ACR16 on prolactin secretion in drug-naive and monoamine-depleted rats. Naunyn Schmiedebergs Arch Pharmacol 384: 39\u201345.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"BFnpp2014195_CR32","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/mp.2012.3","volume":"18","author":"K Sahlholm","year":"2013","unstructured":"Sahlholm K, Arhem P, Fuxe K, Marcellino D (2013). The dopamine stabilizers ACR16 and (\u2212)-OSU6162 display nanomolar affinities at the sigma-1 receptor. Mol Psychiatry 18: 12\u201314.","journal-title":"Mol Psychiatry"},{"key":"BFnpp2014195_CR33","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1176\/ajp.156.6.876","volume":"156","author":"P Seeman","year":"1999","unstructured":"Seeman P, Tallerico T (1999). Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. Am J Psychiatry 156: 876\u2013884.","journal-title":"Am J Psychiatry"},{"key":"BFnpp2014195_CR34","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1021\/jm00043a013","volume":"37","author":"C Sonesson","year":"1994","unstructured":"Sonesson C, Lin CH, Hansson L, Waters N, Svensson K, Carlsson A et al (1994). Substituted (S)-phenylpiperidines and rigid congeners as preferential dopamine autoreceptor antagonists: synthesis and structure-activity relationships. J Med Chem 37: 2735\u20132753.","journal-title":"J Med Chem"},{"key":"BFnpp2014195_CR35","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1002\/hup.1250","volume":"26","author":"N Sugawara","year":"2011","unstructured":"Sugawara N, Yasui-Furukori N, Fujii A, Saito M, Sato Y, Nakagami T et al (2011). No association between bone mass and prolactin levels among patients with schizophrenia. Hum Psychopharmacol 26: 596\u2013601.","journal-title":"Hum Psychopharmacol"},{"key":"BFnpp2014195_CR36","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.neuroimage.2004.10.017","volume":"24","author":"C Svarer","year":"2005","unstructured":"Svarer C, Madsen K, Hasselbalch SG, Pinborg LH, Haugbol S, Frokjaer VG et al (2005). MR-based automatic delineation of volumes of interest in human brain PET images using probability maps. Neuroimage 24: 969\u2013979.","journal-title":"Neuroimage"},{"key":"BFnpp2014195_CR37","unstructured":"Svensson KA, Falcone JF, Johansson AM, Perry KW, Fell MA (2009). The actions of the dopamine stabilizer ACR16, but not (\u2212)-OSU6162, in behavioral and neurochemical assays are not dependent on the presence of functional D2 receptors. Society for Neuroscience (Washington, DC), Annual Meeting; 9\u201313 Nov 2009; San Diego, CA, USA."},{"key":"BFnpp2014195_CR38","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1177\/0269881111435251","volume":"26","author":"ET Te Beek","year":"2012","unstructured":"Te Beek ET, de BP, Moerland M, Schmidt ME, Hoetjes NJ, Windhorst AD et al (2012). In vivo quantification of striatal dopamine D2 receptor occupancy by JNJ-37822681 using [11C]raclopride and positron emission tomography. J Psychopharmacol 26: 1128\u20131135.","journal-title":"J Psychopharmacol"},{"key":"BFnpp2014195_CR39","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1212\/WNL.53.7.1605","volume":"53","author":"J Tedroff","year":"1999","unstructured":"Tedroff J, Ekesbo A, Sonesson C, Waters N, Carlsson A (1999). Long-lasting improvement following (\u2212)-OSU6162 in a patient with Huntington's disease. Neurology 53: 1605\u20131606.","journal-title":"Neurology"},{"key":"BFnpp2014195_CR40","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.tins.2004.06.006","volume":"27","author":"P Voorn","year":"2004","unstructured":"Voorn P, Vanderschuren LJMJ, Groenewegen HJ, Robbins TW, Pennartz CMA (2004). Putting a spin on the dorsal-ventral divide of the striatum. Trends Neurosci 27: 468\u2013474.","journal-title":"Trends Neurosci"},{"key":"BFnpp2014195_CR41","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1124\/dmd.30.12.1372","volume":"30","author":"LC Wienkers","year":"2002","unstructured":"Wienkers LC, Wynalda MA (2002). Multiple cytochrome P450 enzymes responsible for the oxidative metabolism of the substituted (S)-3-phenylpiperidine, (S,S)-3-[3-(methylsulfonyl)phenyl]-1-propylpiperidine hydrochloride, in human liver microsomes. Drug Metab Dispos. 30: 1372\u20131377.","journal-title":"Drug Metab Dispos."},{"key":"BFnpp2014195_CR42","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1097\/01.WCB.0000033967.83623.34","volume":"22","author":"Y Wu","year":"2002","unstructured":"Wu Y, Carson RE (2002). Noise reduction in the simplified reference tissue model for neuroreceptor functional imaging. J Cereb Blood Flow Metab 22: 1440\u20131452.","journal-title":"J Cereb Blood Flow Metab"},{"key":"BFnpp2014195_CR43","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1124\/dmd.108.025478","volume":"37","author":"S Yamazaki","year":"2009","unstructured":"Yamazaki S, Toth LN, Kimoto E, Bower J, Skaptason J, Romero D et al (2009). Application of stable isotope methodology in the evaluation of the pharmacokinetics of (S,S)-3-[3-(methylsulfonyl)phenyl]-1-propylpiperidine hydrochloride in rats. Drug Metab Dispos 37: 937\u2013945.","journal-title":"Drug Metab Dispos"},{"key":"BFnpp2014195_CR44","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/S0893-133X(02)00304-4","volume":"27","author":"F Yokoi","year":"2002","unstructured":"Yokoi F, Gr\u00fcnder G, Biziere K, Stephane M, Dogan AS, Dannals RF et al (2002). Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology 27: 248\u2013259.","journal-title":"Neuropsychopharmacology"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/npp2014195.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/npp2014195","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/npp2014195.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T23:48:55Z","timestamp":1684453735000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/npp2014195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,5]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["BFnpp2014195"],"URL":"https:\/\/doi.org\/10.1038\/npp.2014.195","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,5]]},"assertion":[{"value":"23 December 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2014","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2014","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2014","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}